Form 4 Filing for BridgeBio Pharma, Inc. by Hassan Fred

This filing details a Form 4 submission for BridgeBio Pharma, Inc. (BBIO) by Hassan Fred, who is a director of the company. The filing indicates the grant of restricted stock units (RSUs) under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. These RSUs vest in full on June 22, 2027, contingent upon Mr. Fred's continued service on the board. Each RSU represents a right to one share of the Issuer's Common Stock. Additionally, a stock option to purchase Common Stock was granted, with the underlying shares vesting on June 22, 2027, also subject to continued board service. The transaction date for these events is June 22, 2026. Mr. Fred acquired 3,990 shares of Common Stock and was granted stock options for 5,277 shares. Following these transactions, Mr. Fred directly holds 29,879 shares of Common Stock and 5,277 shares underlying the stock option.